Deucrictibant

Deucrictibant is an investigational new drug that is being evaluated by Pharvaris for the treatment of hereditary angioedema (HAE). It is a bradykinin receptor B2 antagonist which blocks bradykinin-driven swelling attacks which is a characteristic of HAE. Deucrictibant contains a deuterium atom to stabilize it against metabolism and to prolong the half-life of the drug.
Wikipedia contributors, "Deucrictibant", Wikipedia, revision 1384230263, retrieved 20 November 2026, source, CC BY-SA 4.0.